ANAVEX LIFE SCIENCES CORP.
AVXL$708M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW YORK
Drugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AVXL News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
ANAVEX2-73
Alzheimer's Disease
Mid dose ANAVEX2-73
Alzheimer Disease
ANAVEX2-73 oral liquid
Rett Syndrome
High dose ANAVEX2-73
Parkinsons Disease With Dementia
ANAVEX2-73 Oral
Alzheimer's Disease
ANAVEX3-71 oral capsules
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ANAVEX2-73 | Phase 3 | Alzheimer's Disease | - | - |
Mid dose ANAVEX2-73 | Phase 3 | Alzheimer Disease | - | - |
ANAVEX2-73 oral liquid | Phase 3 | Rett Syndrome | - | - |
High dose ANAVEX2-73 | Phase 3 | Parkinsons Disease With Dementia | - | - |
ANAVEX2-73 Oral | Phase 2 | Alzheimer's Disease | - | - |
ANAVEX3-71 oral capsules | Phase 2 | Schizophrenia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply